- Tiziana Life Sciences reported positive preclinical results for intranasal foralumab in an aging model, positioning nasal anti-CD3 as potential approach for age-related cognitive impairment.
- Data were presented in April 2026, showing treatment reversed key aspects of brain aging and improved cognition.
- Study indicated reduced neuroinflammation tied to microglial activation, supporting a mechanism aimed at lowering inflammation-linked cognitive decline.
- Results also pointed to increased hippocampal neurogenesis and reduced cellular senescence, suggesting potential to support brain repair processes.
- Tiziana highlighted ongoing clinical programs for intranasal foralumab across several neurodegenerative indications while expanding preclinical work in aging.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604010700OMX_____CNEWS_EN_GNW9682550_en) on April 01, 2026, and is solely responsible for the information contained therein.
Comments